Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

ResearchHub

Research, connected

Explore the graph

X

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Help Article feed Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal

The Lancet Haematology

2352-3026 · Elsevier BV

17 verified public works

Browse all journals →

From survival to self-determination: the chronic warrior

2026 · 0 citations

From pain to purpose: my thalassaemia journey

2026 · 0 citations

Bridging the thalassaemia divide in south and southeast Asia

2026 · 0 citations

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration

2026 · 0 citations

MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study

2026 · 0 citations

Thalassaemia revisited: whose progress?

2026 · 0 citations

The expanding therapeutic landscape of β-thalassaemia

2026 · 0 citations

Rethinking the possibilities of adult ring sideroblastic anaemia

2026 · 0 citations

Rethinking anti-BCMA T-cell engager design

2026 · 0 citations

α-thalassaemia: an overlooked disease entering a new era

2026 · 0 citations

At the heart of unmet need: TP53 myeloid neoplasms

2026 · 0 citations

Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial

2026 · 0 citations

Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)

2026 · 0 citations

Integrating sexual health into sickle cell disease care

2026 · 0 citations

Vernon Louw: expanding access to clinical haematology in Africa

2026 · 0 citations

From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease?

2026 · 0 citations

Personalising AML treatment: beyond age and fitness

2026 · 0 citations

Page 1 of 1